Up-to-Date Knowledge on Osteoporosis Treatment Selection in Postmenopausal Women

The concept of a super-aged society has led to a steady increase in the average lifespan and hence, interest in a healthy life has increased. Aging is a major risk factor for many diseases, including osteoporosis. Osteoporotic fractures have a significant impact on the quality of life of the elderly and hence, it is pivotal to provide effective treatment of osteoporosis after menopause. Osteoporosis requires proper management and the treatment must be centered on long-term goals. New drugs with diverse mechanisms have been developed for treating osteoporosis. Current management of osteoporosis generally focuses on the importance of risk-based strategies to maximize the effectiveness of existing treatments and mitigate potential negative side-effects. Additionally, there is a need for sequential treatment of osteoporosis in the future. This review discusses the dynamic strategies for osteoporosis treatment and the importance of long-term management in postmenopausal women.

[1]  E. Lewiecki,et al.  Romosozumab and antiresorptive treatment: the importance of treatment sequence , 2022, Osteoporosis International.

[2]  I. Laura,et al.  Which treatment to prevent an imminent fracture? , 2021, Bone reports.

[3]  Jacques P. Brown,et al.  Skeletal responses to romosozumab after 12 months of denosumab , 2021, JBMR plus.

[4]  C. Gregson,et al.  Anabolic treatments for osteoporosis in postmenopausal women , 2021, Faculty reviews.

[5]  M. Saito,et al.  Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: A prospective cohort study , 2021, Bone reports.

[6]  M. Yavropoulou,et al.  Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review , 2021, Journal of clinical medicine.

[7]  K. Ebina,et al.  Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis. , 2020, Bone.

[8]  N. Watts,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. , 2020, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[9]  R. Eastell,et al.  Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update. , 2020, The Journal of clinical endocrinology and metabolism.

[10]  B. Langdahl.  Overview of treatment approaches to osteoporosis , 2020, British journal of pharmacology.

[11]  S. Reichenbach,et al.  A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains , 2020, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  N. Pannacciulli,et al.  Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates , 2019, Osteoporosis International.

[13]  P. Ebeling,et al.  Bone Mineral Density After Transitioning From Denosumab to Alendronate , 2019, The Journal of clinical endocrinology and metabolism.

[14]  Fares Alahdab,et al.  Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis. , 2019, The Journal of clinical endocrinology and metabolism.

[15]  R. Eastell,et al.  Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. , 2019, The Journal of clinical endocrinology and metabolism.

[16]  K. Åkesson,et al.  Risk of imminent fracture following a previous fracture in a Swedish database study , 2019, Osteoporosis International.

[17]  A. Grauer,et al.  FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  A. Grauer,et al.  Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis , 2017, The New England journal of medicine.

[19]  A. Taguchi,et al.  Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients , 2016, Osteoporosis International.

[20]  A. Grauer,et al.  Romosozumab Treatment in Postmenopausal Women with Osteoporosis. , 2016, The New England journal of medicine.

[21]  Hang Lee,et al.  Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial , 2015, The Lancet.

[22]  Yunmi Kim,et al.  [Gender difference in osteoporosis prevalence, awareness and treatment: based on the Korea national health and nutrition examination survey 2008~2011]. , 2015, Journal of Korean Academy of Nursing.

[23]  H. Yoshikawa,et al.  The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis , 2015, Journal of Bone and Mineral Metabolism.

[24]  N. Freemantle,et al.  Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women , 2011, Osteoporosis International.

[25]  Claus Christiansen,et al.  Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3‐Year, Randomized, Placebo‐, and Active‐Controlled Clinical Trial , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  J. Reginster,et al.  Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. , 2002, The Journal of clinical endocrinology and metabolism.